These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22135044)

  • 21. Benefits and risks of oral contraceptive use.
    Williams RS
    Postgrad Med; 1992 Nov; 92(7):155-7, 161-2, 168-71. PubMed ID: 1437913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral contraceptives: mechanism of action, dosing, safety, and efficacy.
    Sondheimer SJ
    Cutis; 2008 Jan; 81(1 Suppl):19-22. PubMed ID: 18338654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Oral contraception and its beneficial gynecological effects].
    Belaisch J; Hommais-loufrani B
    Fertil Contracept Sex; 1988 Mar; 16(3 Suppl):3-7. PubMed ID: 12282188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience.
    Wang Y; Nisenblat V; Tao L; Zhang X; Li H; Ma C
    J Gynecol Oncol; 2019 May; 30(3):e49. PubMed ID: 30887764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biology of female sex hormone action in relation to contraceptive agents and neoplasia.
    King RJ
    Contraception; 1991 Jun; 43(6):527-42. PubMed ID: 1651204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin.
    Pearce CL; Chung K; Pike MC; Wu AH
    Cancer; 2009 Feb; 115(3):531-9. PubMed ID: 19127543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta.
    Rodriguez GC; Nagarsheth NP; Lee KL; Bentley RC; Walmer DK; Cline M; Whitaker RS; Isner P; Berchuck A; Dodge RK; Hughes CL
    J Natl Cancer Inst; 2002 Jan; 94(1):50-60. PubMed ID: 11773282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of oral contraceptive progestins on serum copper concentration.
    Berg G; Kohlmeier L; Brenner H
    Eur J Clin Nutr; 1998 Oct; 52(10):711-5. PubMed ID: 9805216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sex steroids and breast cancer prevention.
    Spicer DV; Pike MC
    J Natl Cancer Inst Monogr; 1994; (16):139-47. PubMed ID: 7999456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques.
    Farquhar C; Rombauts L; Kremer JA; Lethaby A; Ayeleke RO
    Cochrane Database Syst Rev; 2017 May; 5(5):CD006109. PubMed ID: 28540977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose oral contraceptives: progestin potency, androgenicity, and atherogenic potential.
    Ellis J
    Clin Ther; 1986; 8(6):607-18. PubMed ID: 3539347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis?
    Rodriguez GC; Walmer DK; Cline M; Krigman H; Lessey BA; Whitaker RS; Dodge R; Hughes CL
    J Soc Gynecol Investig; 1998; 5(5):271-6. PubMed ID: 9773403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hormone therapy and ovarian cancer.
    Mørch LS; Løkkegaard E; Andreasen AH; Krüger-Kjaer S; Lidegaard O
    JAMA; 2009 Jul; 302(3):298-305. PubMed ID: 19602689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.
    Maxwell GL; Schildkraut JM; Calingaert B; Risinger JI; Dainty L; Marchbanks PA; Berchuck A; Barrett JC; Rodriguez GC
    Gynecol Oncol; 2006 Nov; 103(2):535-40. PubMed ID: 16740300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Oral contraceptives and endometrial and ovarian carcinomas].
    Medl M
    Gynakol Geburtshilfliche Rundsch; 1998; 38(2):105-8. PubMed ID: 9815528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of oral contraceptives and parity on ovarian cancer trends in women under 55 years of age.
    Villard-Mackintosh L; Vessey MP; Jones L
    Br J Obstet Gynaecol; 1989 Jul; 96(7):783-8. PubMed ID: 2788456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Worldwide variations in the lifetime probability of reproductive cancer in women: implications of best-case, worst-case, and likely-case assumptions about the effect of oral contraceptive use.
    Petitti DB; Porterfield D
    Contraception; 1992 Feb; 45(2):93-104. PubMed ID: 1559340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonsteroidal antiinflammatory drugs and progestins synergistically enhance cell death in ovarian epithelial cells.
    Rodriguez GC; Turbov JM; Berchuck A; Stack MS; Hurteau JA; Thaete LG; Barry CP
    Am J Obstet Gynecol; 2012 Mar; 206(3):253.e1-9. PubMed ID: 22206747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prevention of breast cancer through reduced ovarian steroid exposure.
    Spicer DV; Pike MC
    Acta Oncol; 1992; 31(2):167-74. PubMed ID: 1622631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.